Solara Active Pharma Sciences Limited (BOM:541540)
India · Delayed Price · Currency is INR 607.15
-19.10 (-3.05%)
At close: Aug 26, 2025
BOM:541540 Revenue
Solara Active Pharma Sciences had revenue of 3.19B INR in the quarter ending June 30, 2025, a decrease of -12.20%. This brings the company's revenue in the last twelve months to 12.39B, down -4.67% year-over-year. In the fiscal year ending March 31, 2025, Solara Active Pharma Sciences had annual revenue of 12.84B, down -0.40%.
Revenue (ttm)
12.39B
Revenue Growth
-4.67%
P/S Ratio
2.38
Revenue / Employee
5.75M
Employees
2,156
Market Cap
29.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.84B | -51.60M | -0.40% |
| Mar 31, 2024 | 12.89B | -1.55B | -10.73% |
| Mar 31, 2023 | 14.44B | 1.75B | 13.83% |
| Mar 31, 2022 | 12.68B | -3.49B | -21.56% |
| Mar 31, 2021 | 16.17B | 2.95B | 22.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,765.41B |
| HDFC Bank | 2,736.06B |
| Bharti Airtel | 1,839.41B |
| Tata Consultancy Services | 2,561.48B |
| ICICI Bank | 2,054.85B |
| State Bank of India | 3,503.84B |
| Infosys | 1,672.76B |
| Hindustan Unilever | 639.28B |
Solara Active Pharma Sciences News
- 3 months ago - Solara Active Pharma shares rise 4% after Ambernath facility clears USFDA inspection with zero observations - Business Upturn
- 6 months ago - Solara Active Pharma shares down 5% as Managing Director Poorvank Purohit resigns - Business Upturn
- 7 months ago - Solara Active Pharma Sciences announces demerger of CRAMS and Polymers business - Business Upturn
- 7 months ago - Solara Active Pharma Sciences Q3 FY25 Results: Revenue up 41.6% YoY to Rs 300.31 crore - Business Upturn